Compared with other oral hypoglycemic agents, the prevalence of PD when using DPP4 inhibitors and GLP-1RAs was shown to be 36-60% lower (76)
00:04:03 Vickie Danaher For example, GLP-1 increases insulin secretion from the pancreas
Explore the case study: #ClinicalTrials #GLP1 To view or add a comment, sign in Study setup timelines can have a significant impact on the pace of a GLP1 trial, particularly when global logistics, site readiness, and assessment deployment all need to align
As your symptoms improve, you might only need them every few months or so
This strict protocol is critical because globally, 10-15% of untreated cases lead to neuropathy within just six months
For dosing protocols and titration schedules, see our Cagrilintide Dosing Guide